Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18624214 | 0.84 | LPL (0.41) | LPLLIPGCYP1A2CYP2D6KMT2A | |
| SCHEMBL19037725 | 0.82 | LPL (0.40) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL19037728 | 0.81 | LIPG (0.42) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL20655953 | 0.80 | LIPG (0.44) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL31261579 | 0.79 | LIPG (0.50) | LPLLIPGCYP1A2CYP2D6KMT2A | |
| SCHEMBL17739624 | 0.79 | LIPG (0.50) | LPLLIPGCYP1A2CYP2D6KMT2A | |
| SCHEMBL18267531 | 0.79 | LPL (0.38) | LPLLIPGCYP1A2CYP2D6KMT2A | |
| SCHEMBL17923618 | 0.79 | LIPG (0.41) | LPLLIPGPRMT5WDR77CYP1A2 | |
| SCHEMBL22953906 | 0.78 | LPL (0.36) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL13832925 | 0.77 | LIPG (0.44) | LPLLIPGPRMT5WDR77IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10305045-B2 | Organic electroluminescent compound and organic photoelectric apparatus thereof | Shanghai Tianma AM-OLED Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-9923150-B2 | Organic electroluminescent compound and organic photoelectric apparatus thereof | Shanghai Tianma AM-OLED Co., Ltd. (CN) | 2018-03-20 | — | — | US | disclosed |
| US-9923150-B2 | Organic electroluminescent compound and organic photoelectric apparatus thereof | Shanghai Tianma AM-OLED Co., Ltd. (CN) | 2018-03-20 | — | — | US | disclosed |
| US-20170186963-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC PHOTOELECTRIC APPARATUS THEREOF | Shanghai Tianma AM-OLED Co., Ltd. | 2017-06-29 | — | — | US | disclosed |
| US-20170186963-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC PHOTOELECTRIC APPARATUS THEREOF | Shanghai Tianma AM-OLED Co., Ltd. | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170186963-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC PHOTOELECTRIC APPARATUS THEREOF | CCNL2, CCNE2, HCN2 | LPL 3615/4885LIPG 3640/4885PRMT5 2183/4885 |
| US-10305045-B2 | Organic electroluminescent compound and organic photoelectric apparatus thereof | CCNL2, CCNE2, HCN2 | LPL 3615/4885LIPG 3640/4885PRMT5 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.